EUVIMEDEUVIMED entdecken
Übersichtsarbeit

High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation

María-Victoria Mateos iD, Joshua Gustine, Borja Puertas, Noopur Raje iD

Journal of Clinical Oncology · 10.10.2026 · 44 (29) · 2865-2874

DOI: 10.1200/jco-26-00236 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.10.2026. Verfasst von María-Victoria Mateos und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC), Salamanca, Spai…. Hauptthemen laut MEDLINE: Smoldering Multiple Myeloma, Watchful Waiting, Multiple Myeloma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Smoldering multiple myeloma (SMM) is an asymptomatic but biologically heterogeneous plasma cell disorder with a variable risk of progression to multiple myeloma (MM). Accurate risk stratification is essential as only a subset of patients—defined as high-risk SMM —faces a ≥50% risk of progression within 2 years. Contemporary approaches integrating clinical variables, dynamic biomarkers, genomic alterations, and immune profiling have improved risk assessment although some limitations remain. The therapeutic paradigm of SMM is evolving. Randomized phase III trials have consistently shown that early treatment delays progression to MM. Most recently, daratumumab monotherapy became the first approved treatment for high-risk-SMM following the AQUILA trial, which demonstrated a significant progression-free survival benefit (hazard ratio [HR], 0.49 [95% CI, 0.36 to 0.67], P < .001) and a trend toward improved overall survival (OS; HR, 0.52 [95% CI, 0.27 to 0.98]) versus observation. This approval challenges the traditional watch-and-wait approach and establishes early intervention as a validated option for selected patients. However, important uncertainties persist. With modern surveillance and advanced imaging, most progression events are asymptomatic and irreversible end-organ damage is uncommon. OS benefit from early treatment remains inconclusive, particularly in the era of quadruplet regimens available at MM progression. In addition, difficulties in precisely identifying truly high-risk patients raise concerns about overtreatment. Emerging data from intensive regimens, bispecific antibodies, and chimeric antigen receptor -T cell therapies suggest that deep and durable responses—and possibly cure—may be achievable in selected patients with high-risk-SMM, but long-term benefit and safety require further study. In conclusion, following the approval of daratumumab, SMM management should be risk-adapted and patient-centered: observation remains appropriate for some patients, while early treatment should be considered for carefully selected high- and ultrahigh-risk individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Smoldering Multiple MyelomaWatchful WaitingMultiple MyelomaHumansRisk AssessmentAntibodies, MonoclonalDisease ProgressionRisk Factors

Substanzen

daratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC and Centro de Investigación del Cáncer, IBMCC (USAL-CSIC), Salamanca, Spain.
  • Mass General Brigham Cancer Institute, Harvard Medical School, Boston, MA.

ORCID-Profile: María-Victoria Mateos, Noopur Raje

Zitieren

APA

Mateos, M. V., Gustine, J., Puertas, B., & Raje, N. (2026). High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation. Journal of Clinical Oncology, 44(29), 2865-2874. https://doi.org/10.1200/jco-26-00236

Vancouver

Mateos MV, Gustine J, Puertas B, Raje N. High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation. Journal of Clinical Oncology. 2026;44(29):2865-2874. doi:10.1200/jco-26-00236

BibTeX
@article{Mateos2026,
  author = {Mateos, María-Victoria and Gustine, Joshua and Puertas, Borja and Raje, Noopur},
  title = {High-Risk Smoldering Multiple Myeloma: A Review of Controversies in Early Treatment Versus Observation},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {29},
  pages = {2865--2874},
  doi = {10.1200/jco-26-00236}
}
Kostenlos starten →